• Hedgeye Investing Summit: A Special HedgeyeTV Webcast Event

    The sharpest minds in investing discuss the most important market and economic developments and their investing implications. Watch the free replay.

Below is a brief excerpt transcribed from today's edition of The Macro Show hosted by Cannabis Analyst Shayne Laidlaw.

An Update On The Cannabis Industry: A Positive Tailwind - cannabis 2152604 960 720

Here are some recent updates within the cannabis markets that have affected trading and critical roadblocks facing the industry.

Time has shown that the Department of Justice still is slow to approve some large scale deals within the cannabis sector in these past months. Here’s a quick snapshot of a recent black book showing deals that are still pending to go through and are delaying potential upsides in the cannabis stocks to some extent.

An Update On The Cannabis Industry: A Positive Tailwind - 9 11 2019 11 29 36 AM

However as of yesterday, MedMen has gotten past the second request of the HSR Pharmacann acquisition which is a huge step in the right direction. We expect that the DOJ learned a lot more throughout the course of that deal, that they will be able to move much faster through the rest of the deals listed on the chart above.

Quick upcoming M&A transactions should be able to provide a positive tailwind within the cannabis industry and are beneficial to further the success of the market. This acquisition if completed will definitely have a positive effect. The more M&A we see, the better the industry will profit. 

The issue of CBD also remains in the dark on the FDA's potential preliminary regulations towards its use as a food additive or a pure form to be sold across state lines. Despite that however, these companies continue to grow.

An Update On The Cannabis Industry: A Positive Tailwind - 9 11 2019 12 16 00 PM

So we really are bullish on companies that stay out of the way of the FDA and following the supposed rules the best they can. I believe the food additive path is a much harder path from an FDA approval procedure standpoint and companies that stay away from that process will not have to pivot as much.